“It has been another cracking quarter for deals in the pharmaceutical industry, with some big ticket last minute deals making 30 March a manic Monday. The quarter has seen Valeant continue on the M&A trail, with a very interesting acquisition model, which is proving attractive to investors. Looking ahead, the drivers of change for these deals are not going away; and therefore we can expect significant activity to continue in the second quarter. We’re seeing an appetite for late-stage asset acquisitions, to complement existing company portfolios and fill in the gaps, with a particular focus on therapeutic areas.”
T: 020 7311 6497
M: 07467 339 719
Follow us on twitter: @kpmguk
KPMG Press Office: 020 7694 8773
KPMG LLP, a UK limited liability partnership, operates from 22 offices across the UK with approximately 12,000 partners and staff. The UK firm recorded a turnover of £1.9 billion in the year ended September 2014. KPMG is a global network of professional firms providing Audit, Tax, and Advisory services. It operates in 155 countries and has 162,000 professionals working in member firms around the world. The independent member firms of the KPMG network are affiliated with KPMG International Cooperative ("KPMG International"), a Swiss entity. Each KPMG firm is a legally distinct and separate entity and describes itself as such.
This article represents the views of the author only, and does not necessarily represent the views or professional advice of KPMG in the UK.